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Cellular Immunologie In Vitro Studies of Kidney and Bone
Marrow Transplantation: Cytotoxic Τ Cell Activity—an
Advantage or Disadvantage?
E. Goulmy
THE DEVELOPMENT of two cellulartechniques, the mixed lymphocyte cul-
ture' and cell-mediated lympholysis,2 both
now used throughout the world, made it possi-
ble to imitate human organ transplantation
reactions in vitro. Obviously, these assays
reflect only a speeifie aspect of the complex
interactions involved in organ transplantation.
Awareness of the limitations of in vitro obser-
vations is essential when in vivo situations are
to be evaluated. The results of the in vitro
studies presented here must be interpreted
with these restrictions in mind.
The possible clinical relevance of in vitro
analysis of cytotoxic Τ cell (CTL) activity in
renal and bone marrow transplant reeipients
was evaluated.
In kidney transplantation, failure of a
recipient's posttransplantation lymphocytes to
elicit in vitro CTL responses against kidney
donor splenocytes has been shown to correlate
significantly with kidney allograft survival, as
documented in several reports.3"6 The absence
of host CTL directed speeifieally against the
graft histocompatibility antigens has been
observed not only at the effector cell popula-
tion level. Frequency analyses of alloreactive
CTL percursors (CTL-p) in a group of kidney
reeipients demonstrated a decrease in donor-
speeifie CTL-p frequency after transplanta-
tion, whereas the frequency of irrelevant
third-party donor-reactive CTL-p remained
unchanged.7 Thus, it appears that a marked
decrease in the number of in vitro donor-
directed CTL can eoineide with in vivo graft
tolerance. Functional in vitro clonal deletion
can, however, be compensated by the addition
of exogenous IL2.8 It is likely that this balance
can be disturbcd by activation of the immune
System, for example by viral infection. This
hypothesis is supported by the observations of
Grundy and Shearer,9 who reported that in
certain strains of mice an immunoenhancing
effect of the host immune response to foreign
MHC antigens oecurred during murine
cytomegalovirus infection. Moreover, an in-
crement in the number of IL2 receplor
expressing cells at the peak of inflammation
has also been described.10
It is evident that the State of acquired in
vivo immunologic tolerance as reflected by in
vitro kidney donor-speeifie CTL nonrespon-
siveness is the ulümate goal of transplantation
immunologists. What, however, is the signifi-
cance of this goal? Do the patients who dis-
play long term kidney donor-speeifie CTL
nonresponsiveness suffer a disadvantage? The
increased ineidence of malignant tumors
among organ reeipients, as observed in the
past decade.""13 has been attnbuted to immu-
nosuppressive therapy and its effects, but it
might also be a direct consequence of the State
of acquired tolerance. In support of the latter
hypothesis are experimental findings, de-
scribed previously,8 that showed the presence
of "linked nonresponsiveness" after renal
transplantation: lymphocytes from renal allo-
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grafled pdttenls with a well functioning grafl
display Icidney donor-speuhc CTL nonre-
sponsivcness in vitro in addition, these lym-
phocytes do not cxhibit a cytolytic response
upon Stimulation with ccils from unrclated
blood donors sclcctcd for the presence of kid-
ney donor HLA Β locus antigens Morcovcr,
ccils from panel members matched to the
kidney donor at the HI Λ-Β locus but mis-
matched at ihc Λ locus suppressed CT1 activ-
ily agamst any HLA Α antigen presented on
the samc sümulator/targct teil (Tablc I)
Iftolera cc for donor spccihc HLA Β locus
ailoantigens is acquired and consequently the
"linked no ι-responsiveness" becomes mani-
fest, then the Immunologie tolcrance might be
much broader lhan anticipaled The biologic
rclevance of these phenomena with respect to
tumor evolution aftcr rcnal transplantation
has still to bc demonstrated
CTi activity tn bone marrow transplanta
tion was also investigated and tho chnical
relevancc ol in vitro CTI aclivity on the
dcvelopmenl ol graft-t-hosl diseasc (GVHD)
was evaluated Prcvtously we reported Ihc
presence of CTI aclivity in rccipients of an
Hl Α genotypieally identical bone marrow
graft l 4 As ycl anti host CTL activity o! posl-
transplan' pcnpheral blood lymphocytes
(PBl) could bc demonslratt-d mamly (bul not
cxclusivuly) in paticnls suflenng from chronic
GVHD but not in paticnts without GVHD | S
Sonic of these CTI populalions were subsc
quently analy/cd and found to be dirccted
against minor histocompalibihly (minor II)
Table 1 Role of Kidney Donor HLA Β Locus Antigens
in Posttransplant Cytolytic Nonresponsiveness
Unrelatori 8lood Dot
Wth Kidney Donor Arn
Cytolyt c SuppreE
Resporut Respoi
HLA Β ( t- C) but not Α
HLA Α (+ C) but not Β yes
HLA A f
Nono
"Posltransplant penphprai blood lymphocytes from CML
nonrpsponsive recipients were siimulated in vitro with pither
kidney donor HLA Β (and C) or kidney donor HLA Α (dnd C)
antigens presented on lymphocytes of jnrelated blood
donors
f A n y foretgn HLA Α locus antigen
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antigens requirmg seif HLA class i antigens
for recogmtion Analysis at the population
level reveaied relatively high phenotype fre-
quencies for the minor Η antigens (piovisional
designation HA-l to HA-5) identihed Lim
ited family studies showcd a Mendclian
mode of inhcntance of these anligens The
possibie rclevance of minor Η antigens to the
dcvelopmcnt of GVHD was invcsligatcd by
retrospeetive typing aruilysts ο! Λ serics of
HLA-idcnlical bonc marrow donor/recipicnt
combinations 1o date, the results of this
analysis indicate that incompatibility for onc
(or more) minor II antigen between HLA-
identical bonc marrow donor and rccipient
oecurred prcdominantly in the group of
palienls sutTcnng from (chronic) GVHD 15 In
summary the facls that minor Η antigen-
specific C l L are gencrated from PBl in
patients with chronic GVHD and thal mis
matches of onc of the HA antigens oeeur in
palicnts who sulier from chronic GVHD not
onl> indicate the relalionship between the in
vitro obscrvations and the climcally mani
fested GVHD, but also supporl the hypolhesis
that host-dircclcd minoi Η antigen speufie
CTI play a role in the devclopmcnt of
GVHD The important question is, of coursc,
do these patients beneiit from anlihost CTL
activity' The hypothesis that posl bone mar
row iransplant antihost CTI aclivity may
have a beneficial cHecl is based on ihc
assumption that the posiulaled
 tintileukcmic
polunlial is a desired side efieet of the post
bonc marrow transplanl comphcalion GVII
At present, extensive immunogenctic anal-
yses and tissuc distnbution studies are >n
progress in an attempt to gain Information
aboul the most common (IC, most lmmuno-
genic) human minor Η anligens and lo deter-
mine thcir IOIC in the pathogenesis of GVHD
as well as thcir possibie reievance in the
graft-v-lcukcmid (GVL) rcaclton Hopcfully
such studics will facilitate the search lor the
exacl balancc between GVH and GVL, yield-
mg a higher efheaey for clinical bone marrow
transplantation
CTL ACTIVITIES IN HUMAN ORGAN TRANSPLANTATION
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